| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Artificial intelligence to finally enable precision medicine for the management of resected non-small-cell lung cancer
|
Chouaïd, C.
|
|
|
34 |
7 |
p. 565-566
|
artikel
|
| 2 |
Circulating tumor DNA analysis of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor treated with avapritinib or regorafenib ☆
|
Serrano, C.
|
|
|
34 |
7 |
p. 615-625
|
artikel
|
| 3 |
Comment on ‘Therapeutic drug monitoring-based precision dosing of oral targeted therapies in oncology: a prospective multicenter study’ by Dr Steffie L. Groenland et al.
|
Rubovszky, G.
|
|
|
34 |
7 |
p. 628-629
|
artikel
|
| 4 |
Corrigendum to “Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up”
|
Fassnacht, M.
|
|
|
34 |
7 |
p. 631
|
artikel
|
| 5 |
Corrigendum to “HLA class II immunogenic mutation burden predicts response to immune checkpoint blockade”
|
Shao, X.M.
|
|
|
34 |
7 |
p. 634
|
artikel
|
| 6 |
Corrigendum to “78P Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced biliary tract cancer (BTC)”
|
Oh, D.
|
|
|
34 |
7 |
p. 633
|
artikel
|
| 7 |
Corrigendum to “Targeting the complexity of ERBB2 biology in gastroesophageal carcinoma”
|
Augustin, J.E.
|
|
|
34 |
7 |
p. 632
|
artikel
|
| 8 |
Corrigendum to “Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2D metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis”
|
Curigliano, G.
|
|
|
34 |
7 |
p. 630
|
artikel
|
| 9 |
Editorial Board
|
|
|
|
34 |
7 |
p. iii
|
artikel
|
| 10 |
Machine learning-based immune phenotypes correlate with STK11/KEAP1 co-mutations and prognosis in resectable NSCLC: a sub-study of the TNM-I trial
|
Rakaee, M.
|
|
|
34 |
7 |
p. 578-588
|
artikel
|
| 11 |
Molecular markers of metastatic disease in KRAS-mutant lung adenocarcinoma
|
Boiarsky, D.
|
|
|
34 |
7 |
p. 589-604
|
artikel
|
| 12 |
Patient-reported outcomes and hospitalization data in patients with HER2-positive metastatic breast cancer receiving trastuzumab deruxtecan or trastuzumab emtansine in the phase III DESTINY-Breast03 study
|
Curigliano, G.
|
|
|
34 |
7 |
p. 569-577
|
artikel
|
| 13 |
Table of Contents
|
|
|
|
34 |
7 |
p. i-ii
|
artikel
|
| 14 |
Transcriptomic and clinical heterogeneity of metastatic disease timing within metastatic castration-sensitive prostate cancer
|
Sutera, P.A.
|
|
|
34 |
7 |
p. 605-614
|
artikel
|
| 15 |
Trastuzumab deruxtecan for breast cancer: do patients experience a comprehensive benefit?
|
Mosele, F.
|
|
|
34 |
7 |
p. 567-568
|
artikel
|
| 16 |
Why will there never be a randomized trial for NTRK-rearranged tumors?
|
Penel, N.
|
|
|
34 |
7 |
p. 626-628
|
artikel
|
Tijdschrift beschrijving